United Therapeutics | UTHR - Cash And Equivalent


United Therapeutics reported $1.8B in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Amarin USD 143.56M 12.5M Jun/2026
Ardelyx USD 31.21M 36.79M Mar/2026
Baxter International USD 2.15B 133M Jun/2026
Bayer EUR 5.73B 943M Mar/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
Gilead Sciences USD 7.63B 64M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Insmed USD 582.19M 71.74M Mar/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
J&J USD 20.42B 1.27B Jun/2026
Lexicon Pharmaceuticals USD 38.09M 3.76M Mar/2026
Moderna USD 1.72B 185M Jun/2026
Omeros USD 1.9M 2.36M Jun/2025
Pfizer USD 976M 727M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Teva Pharmaceutical Industries USD 3.74B 185M Mar/2026
United Therapeutics USD 1.8B 523.5M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026